American Journal of Bioethics 6 (5):W1-W5 (2006)
This article endeavors to place into context recent developments surrounding the United States Food and Drug Administration recent approval of BiDil? (isosorbide dinitrate/hydralazine hydrochloride) (NitroMed, Inc., Lexington, MA) as the first ever race-specific drug?in this case to treat heart failure in African Americans. It focuses in particular on both commercial incentives and statistical manipulation of medical data as framing the drive to bring BiDil to market as a race-specific drug. In current discourse about pharmacogenomics, targeting a racial audience is perceived as necessary because at this point the technology and resources do not exist to scan efficiently every individual's genetic profile. The article argues that medical researchers may say they are using race as a surrogate to target biology in drug development, but corporations are using biology as a surrogate to target race in drug marketing. Pharmacogenomics may hold great promise, but on our way to that Promised Land, it is imperative to review such short cuts with a critical eye
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
References found in this work BETA
Getting the Numbers Right: Statistical Mischief and Racial Profiling in Heart Failure Research.Jonathan Kahn - 2003 - Perspectives in Biology and Medicine 46 (4):473-483.
Citations of this work BETA
No citations found.
Similar books and articles
Grassroots Marketing in a Global Era: More Lessons From BiDil.Britt M. Rusert & Charmaine D. M. Royal - 2011 - Journal of Law, Medicine & Ethics 39 (1):79-90.
The Troubling Persistence of Race in Pharmacogenomics.Jonathan Kahn - 2012 - Journal of Law, Medicine & Ethics 40 (4):873-885.
“Special Treatment”: BiDil, Tuskegee, and the Logic of Race.Susan M. Reverby - 2008 - Journal of Law, Medicine & Ethics 36 (3):478-484.
Popular Representations of Race: The News Coverage of BiDil.Timothy Caulfield & Simrat Harry - 2008 - Journal of Law, Medicine & Ethics 36 (3):485-490.
Race-Based Medicine and Justice as Recognition: Exploring the Phenomenon of BiDil.Joon-ho Yu, Sara Goering & Stephanie M. Fullerton - 2009 - Cambridge Quarterly of Healthcare Ethics 18 (1):57.
Pharmacogenomics, Ethics, and Public Policy.Karen Peterson-Iyer - 2008 - Kennedy Institute of Ethics Journal 18 (1):pp. 35-56.
The Likelihood of Deception in Marketing.Homer B. Warren, David J. Burns & James Tackett - 2012 - Business and Professional Ethics Journal 31 (1):109-134.
Ethical Issues of Global Marketing: Avoiding Bad Faith in Visual Representation.Janet Borgerson & Jonathan Schroeder - 2002 - European Journal of Marketing 36 (5/6):570-594.
Genotyping the Future: Scientists' Expectations About Race/ Ethnicity After BiDil.Richard Tutton, Andrew Smart, Paul A. Martin, Richard Ashcroft & George T. H. Ellison - 2008 - Journal of Law, Medicine & Ethics 36 (3):464-470.
Reconnecting Marketing to Markets.Luís Aráujo, John Finch & Hans Kjellberg (eds.) - 2010 - Oxford University Press.
Epistemological Structures in Marketing.Donald P. Robin - 1991 - Business Ethics Quarterly 1 (2):185-200.
Character and Virtue Ethics in International Marketing: An Agenda for Managers, Researchers and Educators. [REVIEW]Patrick E. Murphy - 1999 - Journal of Business Ethics 18 (1):107 - 124.
Added to index2010-09-14
Total downloads13 ( #350,328 of 2,158,887 )
Recent downloads (6 months)1 ( #353,783 of 2,158,887 )
How can I increase my downloads?